Health Times of Rhode Island
SEE OTHER BRANDS

Your health and wellness news from Rhode Island

Health Times of Rhode Island: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Times of Rhode Island.

Press releases published on September 1, 2025

Bone Marrow Failure Market Growth Accelerates with Advances in Cell and Gene Therapy | DelveInsight

Bone Marrow Failure Market Growth Accelerates with Advances in Cell and Gene Therapy | DelveInsight

New York, USA, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Bone Marrow Failure Market Growth Accelerates with Advances in Cell and Gene Therapy | DelveInsight The bone marrow failure market is witnessing steady growth driven by the increasing prevalence of aplastic …

Healthcare Champions Launch Public Education Campaign to Address New Mexico’s Medical Access Crisis

Healthcare Champions Launch Public Education Campaign to Address New Mexico’s Medical Access Crisis

Santa Fe, NM, Sept. 01, 2025 (GLOBE NEWSWIRE) -- A new public education campaign has been launched by Patient-Led NM, founded by the New Mexico Medical Society, New Mexico Hospital Association, Sacramento Mountains Foundation, and the Greater Albuquerque …

KFSHRC to Participate as Strategic Partner in C3 Davos of Healthcare New York Summit

KFSHRC to Participate as Strategic Partner in C3 Davos of Healthcare New York Summit

NEW YORK, Sept. 01, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital …

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 eye drops in diabetic macular edema (DME) to be presented …

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK and US media.  HERNEXEOS® (zongertinib tablets) has been approved based on an objective response rate of 71% (N=75), as demonstrated in the Beamion-LUNG 1 clinical trial1 Zongertinib recently received Breakthrough …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions